Ernst-Jan Maria Speel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ernst-Jan Maria Speel has a total of 681 co-authors. Here are the top co-authors by number of shared publications:
- Imke Demers
Department of Pathology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands
8 shared publications - Jens Peter Klussmann
Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany
7 shared publications Jules L. Derks
7 shared publications- Nora Wuerdemann
Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany
7 shared publications Anne-Marie C. Dingemans
6 shared publications- Axel Zur Hausen
Department of Pathology, GROW‐Research Institute for Oncology and Reproduction Maastricht University Medical Centre+ Maastricht the Netherlands
6 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (11)
Controversies in NEN : An ENETS position statement on the diagnosis and treatment of mixed neuroendocrine/non‐neuroendocrine neoplasms of the digestive system
Mixed neuroendocrine/non‐neuroendocrine neoplasms (MiNEN) of the digestive system are rare epithelial malignancies characterised by the coexistence of neuroendocrine and non‐neuroendocrine neoplasm components within the same lesion, where each component must account for at least 30% of the total tumour cell population. Despite growing recognition, MiNEN remain diagnostically and therapeutically challenging because of marked morphological heterogeneity, biological plasticity, and limited evidence guiding management. Recent molecular studies support a common clonal origin with subsequent divergent differentiation, although the mechanisms underlying progression and treatment resistance remain incompletely understood. This ENETS position statement summarises current evidence and expert opinion regarding the diagnosis and treatment of digestive MiNEN, focusing on major controversies in pathology, molecular biology, imaging, and management. Key diagnostic issues include the arbitrary 30% cutoff defining MiNEN, sampling limitations in biopsy specimens, intra‐tumoural heterogeneity, and the distinction between amphicrine and collision neoplasms. Molecular profiling increasingly demonstrates shared genomic alterations between distinct components and may identify potentially actionable targets, including high level of microsatellite instability (MSI‐high) or deficient mismatch repair (dMMR) and V‐RAF murine sarcoma viral oncogene homolog B1 ( BRAF ) alterations in selected cases. Clinical management should be individualised according to anatomical site, stage, differentiation and proliferation of each component, and the histology of metastatic disease when available. Surgery is the main potentially curative approach for localised resectable disease. Perioperative and metastatic systemic treatments are extrapolated predominantly from site‐specific adenocarcinoma and poorly differentiated neuroendocrine carcinoma (NEC) practice; no regimen has been prospectively established as superior specifically for MiNEN. Given the rarity and complexity of MiNEN, multidisciplinary management in expert centres, centralised pathological review, and international collaborative registries are essential to improve diagnostic standardisation and optimise treatment strategies.
- 9 November 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (11)
Controversies in NEN : An ENETS position statement on the diagnosis and treatment of mixed neuroendocrine/non‐neuroendocrine neoplasms of the digestive system
Mixed neuroendocrine/non‐neuroendocrine neoplasms (MiNEN) of the digestive system are rare epithelial malignancies characterised by the coexistence of neuroendocrine and non‐neuroendocrine neoplasm components within the same lesion, where each component must account for at least 30% of the total tumour cell population. Despite growing recognition, MiNEN remain diagnostically and therapeutically challenging because of marked morphological heterogeneity, biological plasticity, and limited evidence guiding management. Recent molecular studies support a common clonal origin with subsequent divergent differentiation, although the mechanisms underlying progression and treatment resistance remain incompletely understood. This ENETS position statement summarises current evidence and expert opinion regarding the diagnosis and treatment of digestive MiNEN, focusing on major controversies in pathology, molecular biology, imaging, and management. Key diagnostic issues include the arbitrary 30% cutoff defining MiNEN, sampling limitations in biopsy specimens, intra‐tumoural heterogeneity, and the distinction between amphicrine and collision neoplasms. Molecular profiling increasingly demonstrates shared genomic alterations between distinct components and may identify potentially actionable targets, including high level of microsatellite instability (MSI‐high) or deficient mismatch repair (dMMR) and V‐RAF murine sarcoma viral oncogene homolog B1 ( BRAF ) alterations in selected cases. Clinical management should be individualised according to anatomical site, stage, differentiation and proliferation of each component, and the histology of metastatic disease when available. Surgery is the main potentially curative approach for localised resectable disease. Perioperative and metastatic systemic treatments are extrapolated predominantly from site‐specific adenocarcinoma and poorly differentiated neuroendocrine carcinoma (NEC) practice; no regimen has been prospectively established as superior specifically for MiNEN. Given the rarity and complexity of MiNEN, multidisciplinary management in expert centres, centralised pathological review, and international collaborative registries are essential to improve diagnostic standardisation and optimise treatment strategies.
- Open Access
- 21 September 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (11)
OTP, CD44, and Ki-67 Immunohistochemistry to Predict Prognosis in Preoperative Lung Neuroendocrine Tumor Biopsy Specimens
- 21 September 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (11)
Open AccessOTP, CD44, and Ki-67 Immunohistochemistry to Predict Prognosis in Preoperative Lung Neuroendocrine Tumor Biopsy Specimens
- 28 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109514
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer
- 28 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109514
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer
- 29 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108783
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
- 29 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108783
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
- Open Access
- 25 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (12) , 1174-1188
Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing
- 25 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (12) , 1174-1188
Open AccessAnalytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing
- Open Access
- 15 August 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 215, 104901
Clinical insight on the pathway of SLFN11 as emergent biomarker in SCLC
- 15 August 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 215, 104901
Open AccessClinical insight on the pathway of SLFN11 as emergent biomarker in SCLC
- Open Access
- 9 August 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (12) , e70080
Controversies in NEN : An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract
Grade 3 neuroendocrine tumours (NET G3) represent approximately 20% of high‐grade neuroendocrine neoplasms, and the recent identification of this entity has given rise to many unanswered questions relating to clinical management. The prognosis for these patients is worse than for those with Grade 1–2 well‐differentiated NET, but better than for those with Grade 3 poorly differentiated neuroendocrine carcinoma. This consensus statement aims to address some uncertainties and explore unmet needs in the management of patients with NET G3. Firstly, the role of surgery in localised disease will be discussed as well as the dilemma in relation to the use of neo‐adjuvant and/or adjuvant treatment in this setting. Treatment of oligometastatic digestive NET G3 will also be examined, including the positioning of surgery and ablative therapy. In the advanced setting, traditionally, chemotherapy in the form of temozolomide/capecitabine or 5‐fluorouracil‐based therapies, rather than platinum/etoposide, is considered a first‐line treatment option, with second‐line therapy dependent on what was used first‐line. More recently, following the results of the NETTER‐2 trial, Peptide Receptor Radionuclide Therapy with 177 Lu‐DOTATATE may be an option for selected patients with somatostatin receptor positive NET G3. There is limited data on the use of immunotherapy and targeted therapy in this disease group to date, and some available evidence will be presented. The role for re‐biopsy to guide treatment decision‐making in patients with digestive NET G3 and whether NET G3 outside of the digestive tract should be treated similarly will also be scrutinised. Prospective studies with translational end‐points are required to enable a better understanding of this diagnosis and to facilitate more optimal treatment discoveries.
- 9 August 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (12) , e70080
Open AccessControversies in NEN : An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract
Grade 3 neuroendocrine tumours (NET G3) represent approximately 20% of high‐grade neuroendocrine neoplasms, and the recent identification of this entity has given rise to many unanswered questions relating to clinical management. The prognosis for these patients is worse than for those with Grade 1–2 well‐differentiated NET, but better than for those with Grade 3 poorly differentiated neuroendocrine carcinoma. This consensus statement aims to address some uncertainties and explore unmet needs in the management of patients with NET G3. Firstly, the role of surgery in localised disease will be discussed as well as the dilemma in relation to the use of neo‐adjuvant and/or adjuvant treatment in this setting. Treatment of oligometastatic digestive NET G3 will also be examined, including the positioning of surgery and ablative therapy. In the advanced setting, traditionally, chemotherapy in the form of temozolomide/capecitabine or 5‐fluorouracil‐based therapies, rather than platinum/etoposide, is considered a first‐line treatment option, with second‐line therapy dependent on what was used first‐line. More recently, following the results of the NETTER‐2 trial, Peptide Receptor Radionuclide Therapy with 177 Lu‐DOTATATE may be an option for selected patients with somatostatin receptor positive NET G3. There is limited data on the use of immunotherapy and targeted therapy in this disease group to date, and some available evidence will be presented. The role for re‐biopsy to guide treatment decision‐making in patients with digestive NET G3 and whether NET G3 outside of the digestive tract should be treated similarly will also be scrutinised. Prospective studies with translational end‐points are required to enable a better understanding of this diagnosis and to facilitate more optimal treatment discoveries.
- Open Access
- 31 January 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (6) , 1797-1810
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
Somatic multigene analysis by next‐generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision‐making. However, with the fast‐growing number of recommended and required genes as well as pan‐cancer biomarkers, small panels have become vastly insufficient. Comprehensive genomic profiling (CGP) is, thus, required to screen for clinically relevant markers. In this multicentric study, we report on an extensive analysis across seven centers comparing the results of the novel OncoDEEP CGP assay with the diagnostically validated TruSight Oncology 500 (TSO500) kit on 250 samples. Overall concordance was 90% for clinically relevant gene variants and >96% for more complex biomarkers. Agreement for fusion detection was 94% for the 11 overlapping clinically actionable driver genes. The higher coverage uniformity of OncoDEEP compared to TSO500 allows users to pool more samples per sequencing run. Tertiary data analysis, including reporting, is integrated in the OncoDEEP solution, whereas this is an add‐on for TSO500. Finally, we showed that, analytically, the OncoDEEP panel performs well, thereby advocating its use for CGP of solid tumors in diagnostic laboratories, providing an all‐in‐one solution for optimal patient management.
- 31 January 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (6) , 1797-1810
Open AccessAnalysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
Somatic multigene analysis by next‐generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision‐making. However, with the fast‐growing number of recommended and required genes as well as pan‐cancer biomarkers, small panels have become vastly insufficient. Comprehensive genomic profiling (CGP) is, thus, required to screen for clinically relevant markers. In this multicentric study, we report on an extensive analysis across seven centers comparing the results of the novel OncoDEEP CGP assay with the diagnostically validated TruSight Oncology 500 (TSO500) kit on 250 samples. Overall concordance was 90% for clinically relevant gene variants and >96% for more complex biomarkers. Agreement for fusion detection was 94% for the 11 overlapping clinically actionable driver genes. The higher coverage uniformity of OncoDEEP compared to TSO500 allows users to pool more samples per sequencing run. Tertiary data analysis, including reporting, is integrated in the OncoDEEP solution, whereas this is an add‐on for TSO500. Finally, we showed that, analytically, the OncoDEEP panel performs well, thereby advocating its use for CGP of solid tumors in diagnostic laboratories, providing an all‐in‐one solution for optimal patient management.
- Open Access
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 214-225
TERT Expression and Clinical Outcome in Pulmonary Carcinoids
PURPOSE: The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric neuroblastoma, in which activation of telomerase reverse transcriptase ( TERT ) is decisive in determining the course of disease. We therefore investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid. METHODS: TERT expression was examined by RNA sequencing in a test cohort and a validation cohort of pulmonary carcinoids (n = 88 and n = 105, respectively). A natural TERT expression cutoff was determined in the test cohort on the basis of the distribution of TERT expression, and its prognostic value was assessed by Kaplan-Meier survival estimates and multivariable analyses. Telomerase activity was validated by telomere repeat amplification protocol assay. RESULTS: Similar to neuroblastoma, TERT expression exhibited a bimodal distribution in pulmonary carcinoids, separating tumors into TERT -high and TERT- low subgroups. A natural TERT cutoff discriminated unfavorable from favorable clinical courses with high accuracy both in the test cohort (5-year overall survival [OS], 0.547 ± 0.132 v 1.0; P < .001) and the validation cohort (5-year OS, 0.788 ± 0.063 v 0.913 ± 0.048; P < .001). In line with these findings, telomerase activity was largely absent in TERT -low tumors, whereas it was readily detectable in TERT- high carcinoids. In multivariable analysis considering TERT expression, histology (typical v atypical carcinoid), and stage (≤IIA v ≥IIB), high TERT expression was an independent prognostic marker for poor survival, with a hazard ratio of 5.243 (95% CI, 1.943 to 14.148; P = .001). CONCLUSION: Our data demonstrate that high TERT expression defines clinically aggressive pulmonary carcinoids with fatal outcome, similar to neuroblastoma, indicating that activation of TERT may be a defining feature of lethal cancers.
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 214-225
Open AccessTERT Expression and Clinical Outcome in Pulmonary Carcinoids
PURPOSE: The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric neuroblastoma, in which activation of telomerase reverse transcriptase ( TERT ) is decisive in determining the course of disease. We therefore investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid. METHODS: TERT expression was examined by RNA sequencing in a test cohort and a validation cohort of pulmonary carcinoids (n = 88 and n = 105, respectively). A natural TERT expression cutoff was determined in the test cohort on the basis of the distribution of TERT expression, and its prognostic value was assessed by Kaplan-Meier survival estimates and multivariable analyses. Telomerase activity was validated by telomere repeat amplification protocol assay. RESULTS: Similar to neuroblastoma, TERT expression exhibited a bimodal distribution in pulmonary carcinoids, separating tumors into TERT -high and TERT- low subgroups. A natural TERT cutoff discriminated unfavorable from favorable clinical courses with high accuracy both in the test cohort (5-year overall survival [OS], 0.547 ± 0.132 v 1.0; P < .001) and the validation cohort (5-year OS, 0.788 ± 0.063 v 0.913 ± 0.048; P < .001). In line with these findings, telomerase activity was largely absent in TERT -low tumors, whereas it was readily detectable in TERT- high carcinoids. In multivariable analysis considering TERT expression, histology (typical v atypical carcinoid), and stage (≤IIA v ≥IIB), high TERT expression was an independent prognostic marker for poor survival, with a hazard ratio of 5.243 (95% CI, 1.943 to 14.148; P = .001). CONCLUSION: Our data demonstrate that high TERT expression defines clinically aggressive pulmonary carcinoids with fatal outcome, similar to neuroblastoma, indicating that activation of TERT may be a defining feature of lethal cancers.
- Open Access
Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study
Background: Liquid biopsy (LBx) assays are transforming precision oncology by the screening of genomic alterations in cfDNA. These assays provide a less invasive alternative to tissue biopsies, which are not always feasible. Molecular pathology laboratories require LBx assays that detect variants at low allele frequencies using standardized methods. Methods: This study evaluated the Hedera Profiling 2 ctDNA test panel (HP2) (Hedera Dx, Epalinges, Switzerland), a hybrid capture-based NGS assay for the detection of somatic alterations from cfDNA. Covering 32 genes, HP2 enables the detection of SNVs, Indels, Fusions, CNVs, and MSI status from a single DNA-only workflow. The analytical performance was assessed using reference standards and a diverse cohort of 137 clinical samples pre-characterized by orthogonal methods. Results: In reference standards at 0.5% VAF, detection sensitivity and specificity for SNVs/Indels were 96.92% and 99.67%, respectively, and 100% each for Fusions. For MSI with VAFs of ≥1% and CNVs with VAFs of ≥ 2% both achieved 100% sensitivity. Conclusion: This international, multicenter analytical performance evaluation study across a large number of hospital laboratories demonstrated high concordance of HP2 assay with orthogonal methods, confirming its significant potential as a highly sensitive, and efficient Pan-Cancer test for future decentralized LBx testing.
Open AccessAnalytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study
Background: Liquid biopsy (LBx) assays are transforming precision oncology by the screening of genomic alterations in cfDNA. These assays provide a less invasive alternative to tissue biopsies, which are not always feasible. Molecular pathology laboratories require LBx assays that detect variants at low allele frequencies using standardized methods. Methods: This study evaluated the Hedera Profiling 2 ctDNA test panel (HP2) (Hedera Dx, Epalinges, Switzerland), a hybrid capture-based NGS assay for the detection of somatic alterations from cfDNA. Covering 32 genes, HP2 enables the detection of SNVs, Indels, Fusions, CNVs, and MSI status from a single DNA-only workflow. The analytical performance was assessed using reference standards and a diverse cohort of 137 clinical samples pre-characterized by orthogonal methods. Results: In reference standards at 0.5% VAF, detection sensitivity and specificity for SNVs/Indels were 96.92% and 99.67%, respectively, and 100% each for Fusions. For MSI with VAFs of ≥1% and CNVs with VAFs of ≥ 2% both achieved 100% sensitivity. Conclusion: This international, multicenter analytical performance evaluation study across a large number of hospital laboratories demonstrated high concordance of HP2 assay with orthogonal methods, confirming its significant potential as a highly sensitive, and efficient Pan-Cancer test for future decentralized LBx testing.